版本:
中国

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

March 28 Acelrx Pharmaceuticals Inc

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

* Acelrx expects an opinion on MAA from committee for medicinal products for human use (CHMP) in first half of 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐